One Stop Shop for All Your Market Research Reports

Global Drugs for Herpes Labialis (Oral Herpes) Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2?3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection. Scope of the Report: This report focuses on the Drugs for Herpes Labialis (Oral Herpes) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US. The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%. Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD. North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%. Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry. The worldwide market for Drugs for Herpes Labialis (Oral Herpes) is expected to grow at a CAGR of roughly 4.9% over the next five years, will reach 2710 million US$ in 2023, from 2040 million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers GSK Novartis Teva Mylan Cadila Apotex Daewoong Pharmaceutical Livzon Luoxin Med shine Bayer (Campho Phenique) Blistex Kelun Group Hikma Haiwang Carmex Cipher Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers Aciclovir Valacyclovir Famciclovir Docosanol Other Market Segment by Applications, can be divided into External Use Oral Injection There are 15 Chapters to deeply display the global Drugs for Herpes Labialis (Oral Herpes) market. Chapter 1, to describe Drugs for Herpes Labialis (Oral Herpes) Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Drugs for Herpes Labialis (Oral Herpes), with sales, revenue, and price of Drugs for Herpes Labialis (Oral Herpes), in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Herpes Labialis (Oral Herpes), for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions; Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12, Drugs for Herpes Labialis (Oral Herpes) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023; Chapter 13, 14 and 15, to describe Drugs for Herpes Labialis (Oral Herpes) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents 1 Market Overview 1.1 Drugs for Herpes Labialis (Oral Herpes) Introduction 1.2 Market Analysis by Type 1.2.1 Aciclovir 1.2.2 Valacyclovir 1.2.3 Famciclovir 1.2.4 Docosanol 1.2.5 Other 1.3 Market Analysis by Applications 1.3.1 External Use 1.3.2 Oral 1.3.3 Injection 1.4 Market Analysis b
Inquiry Before Buying

Request Sample

Share This Report

Our Clients

Payment Mode
Single User US $ 3480
Multi User US $5220
Corporate User US $6960
About this Report
Report ID 30688
Category
  • Pharmaceuticals and Healthcare
Published on 31-Jul
Number of Pages 152
Publisher Name Global Info Research
Editor Rating
★★★★★
★★★★★
(21)